scholarly journals Metastatic renal cell carcinoma presenting as a breast mass in a woman with history of primary breast cancer

2011 ◽  
Vol 94 (6) ◽  
pp. 330
Author(s):  
C Balliauw ◽  
B Termote ◽  
A Van Steen ◽  
P Moerman ◽  
M R Christiaens ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Primary Breast Cancer ◽  
Breast Mass ◽  
History Of

scholarly journals Metastatic Renal Cell Carcinoma to the Parotid Gland in the Setting of Chronic Lymphocytic Leukemia

2012 ◽  
Vol 2012 ◽  
pp. 1-3 ◽  
Author(s):  
Robert Deeb ◽  
Ziying Zhang ◽  
Tamer Ghanem
Keyword(s):  
Renal Cell Carcinoma ◽  
Chronic Lymphocytic Leukemia ◽  
Parotid Gland ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Metastatic Potential ◽  
Lymphocytic Leukemia ◽  
History Of ◽  
Total Parotidectomy

Renal cell carcinoma (RCC) is infamous for its unpredictable behavior and metastatic potential. We report a case of a patient with a complex history of multifocal renal cell carcinoma and chronic lymphocytic leukemia (CLL), who subsequently developed a parotid mass. Total parotidectomy revealed this mass to be an additional site of metastasis which had developed 19 years after his initial diagnosis of RCC.

A FavorAx study of axitinib in favorable risk patients with metastatic renal cell carcinoma.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 666-666
Author(s):  
Ilya Tsimafeyeu ◽  
Pavel Borisov ◽  
Ahmed Abdelgafur ◽  
Roman Leonenkov ◽  
Olga Novikova ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Adverse Events ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Primary Endpoint ◽  
Renal Cell ◽  
Response Rate ◽  
Objective Response ◽  
First Line ◽  
History Of

666 Background: Targeted therapy with axitinib resulted in a greater objective response rate and prolonged progression-free survival (PFS) compared to sorafenib in patients with previously treated metastatic renal cell carcinoma (mRCC) in AXIS study. 75% of patients had intermediate and poor IMDC prognosis. In this phase 2 study, we assessed the activity of axitinib in mRCC patients with favourable risk and a history of prior VEGFR-directed therapy. Methods: Patients were required to have clear cell mRCC, favourable risk according to IMDC criteria, and to have received first-line treatment with sunitinib or pazopanib. Prior treatment with other agents was not permitted. The primary endpoint of the study was PFS. Additional endpoints included response rate, safety, and overall survival (OS). Results: A total of 21 patients were enrolled, 62% of whom were male. Median age was 59 years. 11 (52%) patients had 2 and more metastatic sites. 67% and 33% of patients received first-line sunitinib or pazopanib with a median PFS of 17 months (95% CI 14-20). After a median follow-up of 16 months, the median PFS and OS was not yet reached. The current study did achieve its primary endpoint based on the 10-month PFS of 71.4%. 3 (14.3%) patients had confirmed partial responses and 14 (66.7%) had stable disease. No grade 3/4 treatment-related adverse events were observed; the most frequent grade 1/2 treatment-related adverse events were hypertension (57.1%), fatigue (57.1%), GI (33%) and skin (19%) toxicity. 7 patients had dose-escalation of axitinib and 1 patient had dose reduction. Conclusions: The encouraging PFS and favorable safety profile observed in FavorAx study support the administration of axitinib in mRCC patients with favourable IMDC risk and a history of prior sunitinib or pazopanib. Clinical trial information: NCT02700568.

scholarly journals Metastatic renal cell carcinoma in the head and neck region

2018 ◽  
Vol 4 (4) ◽  
pp. 1092
Author(s):  
Sowjanya Gandla ◽  
Veena Ramaswamy ◽  
Vishal Rao
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Left Kidney ◽  
Neck Region ◽  
Temporal Region ◽  
Head And Neck Region ◽  
History Of ◽  
Left Temporal Region

<p>We describe 3 rare cases of metastatic renal cell carcinoma in the head and neck region. Our first case was a 72 years old male presented with profuse bleeding from the left ear. On examination, proliferative, pink, friable mass was present in the left external auditory canal. On eliciting the detailed history, it was found that patient had renal cell carcinoma in the left kidney four years back and underwent left radical nephrectomy. Patient underwent left lateral temporal bone resection with cul-de-sac closure. Histopathological examination of the specimen showed metastatic renal cell carcinoma. Our second case was a 64 years old male presented with complaints of growth in the oral cavity of 1 month duration. On examination, 5×3 cms proliferative growth was present in the hard palate. Biopsy from the growth in the hard palate showed metastatic renal cell carcinoma. Patient gave history of renal cell carcinoma in the past for which he did not receive treatment. Our third case was a 45 years old male who presented to us with a diffuse swelling in the left temporal region of 2 months duration. On examination, 3×2 cms swelling was present in the left temporal region. Patient had history of renal cell carcinoma of left kidney and underwent left nephrectomy one year prior to the presentation of the left temporal swelling. Ultrasonography guided biopsy of the left temporal region showed metastatic renal cell carcinoma.</p>

scholarly journals Studying the Association Between Breast Cancer and Renal Cell Carcinoma

2021 ◽  
Author(s):  
Khalid A Jazieh ◽  
Firas Baidoun ◽  
Nataly Torrejon ◽  
Zahi Merjaneh ◽  
Anas Saad ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Renal Cell Carcinoma ◽  
Genetic Testing ◽  
Family History ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Case Reports ◽  
Population Data ◽  
Seer Database ◽  
History Of

Abstract Purpose: There are case reports of patients with both primary breast cancer (BC) and renal cell carcinoma (RCC). We explore the association between these two malignancies using SEER population data and our institutional records.Methods: We studied the association between BC and RCC in the 2000-2016 Surveillance, Epidemiology and End Results (SEER) database. We then reviewed our hospital records of patients with both BC and RCC and collected information including personal and family history of cancers, genetic testing, and patient outcomes.Results: Of the 813,477 females diagnosed with BC in the SEER database, 1,914 later developed RCC. The risk of developing RCC was significantly increased within the first six months, 7-12 months, and 1-5 years following BC diagnosis with standardized incidence ratios (SIRs) of 5.08 (95% CI, 4.62- 5.57), 2.09 (95% CI, 1.8-2.42), and 1.15 (95% CI, 1.06-1.24), respectively. Of 56,200 females with RCC, 1,087 later developed BC. The risk of developing BC following RCC was elevated within the first six months (SIR of 1.45 [95% CI, 1.20-1.73]). For our hospital patients, 437 had both BC and RCC. 427 (97.71%) were female, and 358 (81.92%) were white, and breast cancer was diagnosed before RCC in 246 (61.5%) patients. There were 15 germline mutations in those with genetic testing. Conclusion:Our findings suggest that BC patients are at higher risk of developing RCC and vice versa. BC tended to precede RCC, and patients frequently had personal histories of other malignancies and a family history of cancer, particularly BC.

scholarly journals Intramammary Metastasis in a Patient with a History of Renal Cell Carcinoma: A Case Report

2018 ◽  
Vol 11 (2) ◽  
pp. 318-322
Author(s):  
Miyuki Kitahara ◽  
Yasuo Hozumi ◽  
Rio Asada ◽  
Aya Sawa ◽  
Hitoaki Saito ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Needle Biopsy ◽  
Malignant Tumors ◽  
Definitive Diagnosis ◽  
Benign Tumors ◽  
Immunohistochemical Examination ◽  
History Of

Intramammary metastasis of renal cell carcinoma (RCC) is extremely rare, accounting for only 1.5% of all intramammary metastases. Distinguishing intramammary metastases from benign tumors and breast cancer is clinically problematic. Some patients undergo excessive surgery after a misdiagnosis of breast cancer instead of a mammary tumor. We performed a core needle biopsy (CNB) of a breast mass that developed in a 71-year-old woman after surgeries for bilateral RCC and breast cancer, leading to a diagnosis of intramammary metastasis of RCC. In this case, the CNB and immunohistochemical examination were critical for reaching a definitive diagnosis. We conclude that, when examining patients with mammary tumors, establishing their history of malignant tumors may help diagnose intramammary metastasis and select the best treatment strategy.

scholarly journals Metastatic Renal Cell Carcinoma Presenting as Breast Mass in a Male

2018 ◽  
pp. 18-22
Author(s):  
Jaideep Das Gupta ◽  
Indranil Sen ◽  
SP Chowdhury ◽  
Anjan Das
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Breast Mass
Sign in / Sign up

Export Citation Format

Share Document